Livzon Pharma Gains NMPA Green Light for China’s First 11.25 mg Three-Month Leuprorelin Acetate Microspheres

Bulletin Express
09/29

Livzon Pharmaceutical Group Inc. (Livzon Pharma, 01513) announced that its controlling subsidiary, Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd., has received a Drug Supplementary Application Approval Notice (No. 2026B06648) from China’s National Medical Products Administration (NMPA) for Leuprorelin Acetate Microspheres for Injection 11.25 mg, a three-month sustained-release formulation. The product’s National Drug Approval Number (H20269239) is valid through 27 April 2029.

The newly approved specification expands Livzon Pharma’s Leuprorelin portfolio—which already includes 3.75 mg and 1.88 mg doses—and offers extended 12-week dosing for premenopausal breast cancer, prostate cancer and central precocious puberty. Compared with the existing one-month 3.75 mg version, the three-month formulation uses a novel poly(DL-lactide) excipient developed in-house, delivering steadier plasma concentrations and reducing injection frequency, pain and treatment burden.

Development investment for the 11.25 mg product totaled approximately RMB 94.05 million (USD 13.0 million equivalent). According to IQVIA estimates, China’s long-acting gonadotropin-releasing hormone agonist (GnRHa) sustained-release market reached about RMB 10.90 billion (USD 1.50 billion) in 2025, with three-month formulations accounting for 27%. Excluding the originator, Shanghai Livzon is currently the sole domestic holder of marketing approval for this dosage strength.

This approval represents the world’s first GnRH preparation cleared on the basis of a bioequivalence study aligned with U.S. FDA product-specific guidance, closing China’s technological gap in three-month sustained-release microsphere formulations and reinforcing Livzon Pharma’s leadership in microsphere R&D.

Management cautions that pharmaceutical sales remain vulnerable to regulatory changes and market dynamics, advising investors to remain mindful of inherent industry risks.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10